Arena Pharmaceuticals, Inc. (ARNA) Reaches $40.08 After 4.00% Up Move; Two River Bancorp (TRCB) Sentiment Is 1.19

February 13, 2018 - By Clifton Ray

The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a huge mover today! The stock decreased 0.64% or $0.26 during the last trading session, reaching $40.08. About 286,776 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has declined 11.92% since February 13, 2017 and is downtrending. It has underperformed by 28.62% the S&P500.The move comes after 5 months positive chart setup for the $1.57B company. It was reported on Feb, 13 by Barchart.com. We have $41.68 PT which if reached, will make NASDAQ:ARNA worth $62.96 million more.

Two River Bancorp operates as the bank holding firm for Two River Community Bank that provides banking services to small and medium-sized businesses, professionals, and individual consumers. The company has market cap of $141.20 million. The firm accepts deposit products, such as demand, savings, and time deposits; checking and money market accounts; and certificates of deposit. It has a 22.23 P/E ratio. The Company’s loan products include construction and land development loans; commercial and industrial loans; commercial real estate loans; residential real estate loans, such as single-family detached units, individual condominium units, two-to-four family dwelling units, and townhouses; consumer loans comprising home equity lines of credit, home equity loans, personal loans, automobile loans, and overdraft protection; participation loans; and small business administration loans.

Among 8 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Arena Pharmaceuticals had 16 analyst reports since October 28, 2015 according to SRatingsIntel. The company was maintained on Thursday, June 29 by Cantor Fitzgerald. Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rating on Wednesday, November 8. Cantor Fitzgerald has “Buy” rating and $37.0 target. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, January 4. The firm has “Sector Perform” rating given on Wednesday, November 11 by RBC Capital Markets. The rating was maintained by Leerink Swann on Monday, July 17 with “Buy”. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Buy” rating given on Tuesday, July 11 by Cantor Fitzgerald. FBR Capital initiated it with “Outperform” rating and $6 target in Thursday, September 15 report. The rating was upgraded by Wells Fargo on Wednesday, January 3 to “Outperform”. The firm earned “Buy” rating on Wednesday, July 19 by Cantor Fitzgerald. The rating was maintained by Leerink Swann with “Buy” on Wednesday, January 17.

Analysts await Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report earnings on March, 13. They expect $-0.64 earnings per share, down 140.00% or $2.24 from last year’s $1.6 per share. After $-0.65 actual earnings per share reported by Arena Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -1.54% EPS growth.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $1.57 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Mercer Capital Advisers Inc. holds 0.81% of its portfolio in Two River Bancorp for 54,933 shares. Pinnacle Holdings Llc owns 60,766 shares or 0.44% of their US portfolio. Moreover, Maltese Capital Management Llc has 0.25% invested in the company for 148,533 shares. The Illinois-based Banc Funds Co Llc has invested 0.2% in the stock. Raab & Moskowitz Asset Management Llc, a New Jersey-based fund reported 10,947 shares.

Since January 1, 0001, it had 0 insider purchases, and 1 sale for $194,942 activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: